Federal Laboratory Consortium for Technology Transfer

Licensing a diagnostic assay for point-of-care testing

The process of licensing a lab’s diagnostic assay for point-of-care testing begins with a precise intended use. Is the test intended for a hospital bedside, a pharmacy, a GP clinic, an aged-care facility, or a home setting? Each setting changes the evidence, workflow, packaging and regulatory pathway. A licence therefore grants more than access to a method: it provides the know-how needed to build a reliable diagnostic product.

Before contacting a technology transfer office, define the target product profile. Specify the analyte, specimen type, sample-to-answer time, required sensitivity and specificity, test environment, reader compatibility and expected throughput. Distinguish a research assay from a product-ready in vitro diagnostic. This prevents a promising technique from being licensed for an application its validation data cannot support.

Federal laboratories often hold patents, biological materials, software, calibration data and unpublished know-how generated through government-funded research. The commercial partner may need several of these elements, or the laboratory may already offer a partially packaged invention. Licensing therefore starts with a disciplined inventory of what exists, who owns it and which technical gaps must be closed before a product can be sold.

For an Australian sponsor, the destination is a regulated product and a viable local service pathway, not simply an overseas licence. TGA requirements, Australian manufacturing or distribution arrangements, state procurement and reimbursement all shape the business case. A point-of-care assay can suit Australia’s geography: faster results may help when samples travel from regional and remote locations to major laboratories in Sydney, Melbourne, Brisbane or Adelaide.

Turning a laboratory method into a commercial product

A diagnostic assay rarely exists as a self-contained invention. Reagents, extraction steps, controls, specimen collection, instrument software and interpretation rules must work together. A method that performs well with skilled laboratory staff may fail when used intermittently by a nurse, pharmacist or community worker. The target product profile should therefore cover operator training, sample error, connectivity, waste disposal, calibration and maintenance, not merely analytical accuracy.

The transferable package may include a prototype reader, consumable cartridges, reagent formulations, manufacturing records, a clinical protocol and reference data. It may also include rights in a patent or restrictions on a biological material. These assets have different owners and expiry dates. A complete diligence room lets the prospective licensee compare what it is receiving with what it must develop independently.

Commercial screening should test whether the proposed use has an unmet need, a plausible price and a reachable buyer. It should also expose whether the assay depends on expensive equipment, scarce raw materials or a sample preparation step incompatible with a true point-of-care workflow. Early rejection is valuable when the concept lacks a defensible pathway to scale, reimbursement or sustainable margins.

Finding the right federal technology partner

The Federal Laboratory Consortium connects companies and researchers with federally developed technologies and laboratory expertise. Its regional laboratory network spans seven regional areas and can help identify a relevant laboratory, inventor or technology across the United States. Because a search result does not reveal ownership, freedom to operate or commercial readiness, the first contact should come through the relevant federal technology transfer office.

Federal laboratories and their partners may apply for patents under the Bayh–Dole Act, retain government rights, or hold inventions with different funding histories. The sponsor should request a patent schedule, invention disclosure, funding statement, inventorship record and any government march-in or royalty obligations. It should verify that the named licensor can grant the proposed rights and that material transfers and data use are permitted.

The preferred licensee brings more than capital. It needs assay development, quality assurance, regulatory affairs, supply chain and local market access. An early joint development agreement can define work packages, cost sharing, milestones and ownership of new results. This creates evidence before either side signs a broad exclusive licence while preserving a clear path to a definitive agreement if technical and commercial gates are met.

Proving analytical and clinical performance

Analytical validation establishes whether the assay measures what it claims under its intended conditions. For a point-of-care diagnostic, this includes limit of detection and quantification, precision, repeatability, reportable range, linearity, interference, cross-reactivity, hook effect, specimen matrix effects and stability. The protocol must reflect the proposed cartridge, reader, specimen and operator because performance in a central laboratory cannot be transferred automatically to a near-patient setting.

Validation plans should predefine acceptance criteria, sample numbers, controls and statistical methods. A technical resource on analytical validation considerations can support the documentation structure, but the laboratory’s own raw data remain the controlling evidence. Investigate reagent stability, freeze–thaw cycles, shipping conditions, lot consistency and the ability to train new operators.

Clinical validation asks whether the assay performs acceptably in the people and samples that will be used. Australian sites should address disease prevalence, symptomatic versus screening populations and relevant subgroups. Predetermined sensitivity, specificity, confidence intervals and invalid-result rates are stronger than retrospective claims. Human research requires ethics approval, and studies involving Aboriginal and Torres Strait Islander communities should use appropriate community governance and data sovereignty.

Mapping regulatory and quality obligations

In the United States, the FDA pathway depends on intended use and risk. A point-of-care reader may be cleared through 510(k) if an appropriate predicate exists, through De Novo when there is no predicate, or through a higher-risk route where warranted. Laboratory use can also raise CLIA considerations, but CLIA certification and FDA clearance answer different questions. Licensing an assay does not supply either approval.

In Australia, the TGA regulates in vitro diagnostic products under the Therapeutic Goods Act 1989 and associated regulations. Higher-risk IVDs generally require inclusion in the Australian Register of Therapeutic Goods, while risk class, transitional status and the sponsor’s conformity-assessment route determine the exact obligations. An Australian sponsor or authorised local entity should map the manufacturer, device class, quality management system evidence, clinical evidence and labels before agreeing to commercial milestones.

Quality planning should connect ISO 13485-style design controls, supplier qualification, process validation and lot release to the licensed method. Importing finished tests is only one option; local assembly or contract manufacture may improve control but creates new transfer obligations. Australia’s heat can challenge reagent and cartridge stability, while long routes from Melbourne or Sydney to remote clinics make cold-chain capacity and replacement logistics essential. Summer field testing should cover actual transport and storage, not idealised bench conditions.

Market access also needs early modelling. A Medicare Benefits Schedule listing applies only where a test and provider meet the relevant rules; many point-of-care assays are funded through hospitals, aged care, pharmacies or state programmes instead. Contracts must account for consumable cost, throughput, wastage and outcome benefits. Consumer and clinical data should also be handled under the Privacy Act 1988 and applicable Australian privacy principles, with cybersecurity controls for connected readers.

Structuring the licensing agreement

A definitive licence should describe the field of use, territory, exclusivity, permitted affiliates, sublicensing and exact deliverables. It should separate background intellectual property from foreground improvements and define who may prosecute patents, publish results and enforce know-how. Granting rights to manufacture, import, sell, distribute and use the assay avoids gaps that can delay an Australian launch.

Commercial terms can combine an upfront fee, running royalties, minimum annual royalties and milestone payments. Royalties should be tied to net sales or a defensible measure, while milestones can mark technical completion, regulatory clearance and first commercial sale. The agreement should address forecasts, audit rights, minimum performance, order forecasts, quality failures, recalls, regulatory cooperation and what happens if a territory is abandoned.

Risk allocation matters because federal research may be at an early development stage. State who owns new data, methods and improvements, how improvements revert to the licensor, and how the parties will handle infringement claims or freedom-to-operate concerns. Include publication review, confidentiality, supply continuity, insurance and dispute resolution while preserving the licensor’s compliance with government rights and the licensee’s authority to meet TGA and other regulatory duties.

An Australian launch pathway for licensed assays

Execution depends on converting licence terms into a gated development programme with named owners, budgets, decision dates and acceptance criteria. The following measures suit an Australian point-of-care launch because they align scientific evidence, regulatory evidence and a credible route to purchase.

A disciplined licence-to-launch pathway protects the public from weak claims and protects the parties from uncertain development. It also turns publicly funded research into a product that Australian health services can use safely, consistently and at a sustainable cost.